In the sentence "Results of a phase I trial113 demonstrated that an agonist mAb targeting CD40 given as monotherapy has antitumour activity in patients with melanoma or RCC", CD40 should have read OX40. This error has been corrected in the online HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2016.25
Rights and permissions
About this article
Cite this article
Khalil, D., Smith, E., Brentjens, R. et al. Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13, 394 (2016). https://doi.org/10.1038/nrclinonc.2016.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.65
This article is cited by
-
A bibliometric analysis of ferroptosis, necroptosis, pyroptosis, and cuproptosis in cancer from 2012 to 2022
Cell Death Discovery (2023)
-
Overcome tumor relapse in CAR T cell therapy
Clinical and Translational Oncology (2022)
-
Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA
BMC Immunology (2021)
-
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Biomarker Research (2021)
-
Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation
Scientific Reports (2021)
